- Home
- PBYI
as 06-20-2025 3:40pm EST
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 167.3M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 347.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.77 | EPS Growth: | 143.51 |
| 52 Week Low/High: | $2.23 - $4.13 | Next Earning Date: | 07-31-2025 |
| Revenue: | $232,709,000 | Revenue Growth: | 2.68% |
| Revenue Growth (this year): | -3.6% | Revenue Growth (next year): | -0.43% |
Stock Insider Trading Activity of Puma Biotechnology Inc (PBYI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WILSON TROY EDWARD | PBYI | Director | Jun 13 '25 | Sell | $3.40 | 10,800 | $36,720.00 | 43,550 | |
| Dorval Allison | PBYI | Director | Jun 13 '25 | Sell | $3.40 | 11,610 | $39,474.00 | 75,390 | |
| Stuglik Brian M | PBYI | Director | Jun 13 '25 | Sell | $3.39 | 8,100 | $27,459.00 | 94,958 | |
| Cesano Alessandra | PBYI | Director | Jun 13 '25 | Sell | $3.40 | 12,150 | $41,310.00 | 68,850 | |
| Senderowicz Adrian | PBYI | Director | Jun 13 '25 | Sell | $3.40 | 27,000 | $91,800.00 | 27,000 |
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
Zacks
10 days ago
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Simply Wall St.
11 days ago
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing
Business Wire
16 days ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Simply Wall St.
a month ago
3 Promising Penny Stocks With Market Caps Under $200M
Simply Wall St.
a month ago
Puma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable Quality
Simply Wall St.
a month ago
Puma Biotechnology First Quarter 2025 Earnings: Beats Expectations
Compare PBYI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PBYI Puma Biotechnology Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.